Dermal α-synuclein seeding in relation to REM sleep behavior disorder across prodromal and Parkinson disease cohorts
PLOS One · 20.11.2026 · 21 (11) · e0357868
DOI: 10.1371/journal.pone.0357868 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 20.11.2026. Verfasst von Emadoddin Kazemi. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
REM sleep behavior disorder (RBD) is a well-established prodromal manifestation of synucleinopathy and is closely linked to peripheral clinical features in Parkinson disease (PD). Dermal α-synuclein seed amplification assay (SAA) provides a peripheral measure of pathological α-synuclein across these disease stages. We performed a cross-sectional analysis of data from the Parkinson’s Precision Medicine Initiative (PPMI), including controls, participants with polysomnography-confirmed RBD, and participants with PD. Skin SAA positivity and participant-level kinetic measures (area under the curve [AUC], maximum fluorescence [Fmax], and time to threshold [TTT]) were assessed at 1:20 and 1:50 lysate dilutions. Participants with PD were further classified as suspected brain/motor-enriched or body/peripheral-enriched based on prespecified exploratory clinical features. Skin SAA positivity was detected in 53.3% of participants with polysomnography-confirmed RBD compared with none of the controls, and RBD participants showed significantly faster amplification than controls at both lysate dilutions. Within PD, binary SAA positivity was higher in the suspected body/peripheral-enriched than brain/motor-enriched phenotype, but the difference was not statistically significant (83.3% vs 47.6%; p = 0.067). All seven kinetic measures were greater in the suspected body/peripheral-enriched phenotype after false discovery rate correction, but these differences were not retained when RBDSQ total score was removed from the classification. RBDSQ total score was the only clinical variable associated with skin SAA kinetics after correction and was significantly associated with six of the seven kinetic measures. These findings show that dermal α-synuclein seeding is detectable in PSG-confirmed prodromal RBD and is associated with RBD-related clinical features within established PD.
Zitieren
APA
Kazemi, E. (2026). Dermal α-synuclein seeding in relation to REM sleep behavior disorder across prodromal and Parkinson disease cohorts. PLOS One, 21(11), e0357868. https://doi.org/10.1371/journal.pone.0357868
Vancouver
Kazemi E. Dermal α-synuclein seeding in relation to REM sleep behavior disorder across prodromal and Parkinson disease cohorts. PLOS One. 2026;21(11):e0357868. doi:10.1371/journal.pone.0357868
BibTeX
@article{Kazemi2026,
author = {Kazemi, Emadoddin},
title = {Dermal α-synuclein seeding in relation to REM sleep behavior disorder across prodromal and Parkinson disease cohorts},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {11},
pages = {e0357868},
doi = {10.1371/journal.pone.0357868}
}
EUVIMED